Kura Oncology, Inc.KURANASDAQ
Loading
R&D Expense Growth TrendStable
Percentile Rank86
3Y CAGR+71.0%
5Y CAGR+12.7%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+71.0%/yr
vs -40.7%/yr prior
5Y CAGR
+12.7%/yr
Recent acceleration
Acceleration
+111.6pp
Accelerating
Percentile
P86
Within normal range
vs 5Y Ago
1.8x
Solid growth
Streak
3 yr
Consecutive growthStable
| Period | Value |
|---|---|
| 2025 | 47.72% |
| 2024 | 47.50% |
| 2023 | 24.16% |
| 2022 | 9.55% |
| 2021 | 40.27% |
| 2020 | 26.28% |
| 2019 | 2.22% |
| 2018 | 77.05% |
| 2017 | 29.51% |
| 2016 | 14.78% |